ERYP
Income statement / Annual
Last year (2022), ERYTECH Pharma S.A.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, ERYTECH Pharma S.A.'s net income was -$228,000.00.
See ERYTECH Pharma S.A.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$3.36 M |
$4.14 M |
$3.36 M |
$19.72 M |
$10.78 M |
$6.61 M |
$1.80 M |
Cost of Revenue |
$0.00
|
$0.00
|
$57.58 M
|
$52.19 M
|
$33.47 M
|
$25.46 M
|
$19.72 M
|
$10.78 M
|
$6.61 M
|
$5.33 M
|
Gross Profit |
$0.00
|
$0.00
|
-$57.58 M
|
-$48.83 M
|
-$29.33 M
|
-$22.10 M
|
$0.00
|
$0.00
|
$0.00
|
-$3.53 M
|
Gross Profit Ratio |
0
|
0
|
0
|
-14.52
|
-7.09
|
-6.57
|
0
|
0
|
0
|
-1.96
|
Research and Development Expenses |
$19.91 M
|
$45.10 M
|
$57.58 M
|
$52.19 M
|
-$19.72 M
|
-$25.46 M
|
$0.00
|
$0.00
|
$0.00
|
$2.50 M
|
General & Administrative Expenses |
$13.89 M
|
$15.10 M
|
$14.97 M
|
$17.16 M
|
$14.60 M
|
$8.52 M
|
$6.66 M
|
$7.62 M
|
$4.36 M
|
$3.55 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$13.89 M
|
$15.10 M
|
$14.97 M
|
$17.16 M
|
$14.60 M
|
$8.52 M
|
$6.66 M
|
$7.62 M
|
$4.36 M
|
$3.55 M
|
Other Expenses |
-$6.65 M
|
-$3.69 M
|
-$3.72 M
|
-$5.28 M
|
-$4.45 M
|
-$3.10 M
|
-$3.99 M
|
-$2.81 M
|
-$2.03 M
|
-$4.29 M
|
Operating Expenses |
$27.15 M
|
$56.52 M
|
$68.83 M
|
$64.07 M
|
$10.15 M
|
$5.43 M
|
$2.67 M
|
$4.81 M
|
$2.34 M
|
$1.76 M
|
Cost And Expenses |
$27.15 M
|
$56.52 M
|
$68.83 M
|
$64.07 M
|
$43.62 M
|
$30.89 M
|
$22.39 M
|
$15.58 M
|
$8.95 M
|
$7.09 M
|
Interest Income |
$4.45 M
|
$13,000.00
|
$889,000.00
|
$2.95 M
|
$163,000.00
|
$405,000.00
|
$545,000.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$1.36 M
|
$2.14 M
|
$5.35 M
|
$1.53 M
|
$9,000.00
|
$15,000.00
|
$4,000.00
|
$5,000.00
|
$6,801.00
|
$4,656.00
|
Depreciation & Amortization |
-$19.90 M
|
$9.06 M
|
$889,000.00
|
$2.95 M
|
$797,000.00
|
$532,000.00
|
$425,000.00
|
$288,000.00
|
$276,522.00
|
$180,297.00
|
EBITDA |
-$22.69 M |
-$47.46 M |
-$67.94 M |
$5.28 M |
$4.45 M |
$3.36 M |
-$21.47 M |
-$14.72 M |
-$8.60 M |
-$8.00 M |
EBITDA Ratio |
0
|
0
|
0
|
-18.17
|
-9.04
|
-9.81
|
-1.09
|
-1.37
|
-1.3
|
-4.44
|
Operating Income Ratio |
0
|
0
|
0
|
-19.05
|
-10.54
|
-9.18
|
-1.14
|
-1.45
|
-1.35
|
-3.93
|
Total Other Income/Expenses Net |
$3.09 M
|
$2.72 M
|
-$4.47 M
|
-$67.94 M
|
-$42.67 M
|
-$2.64 M
|
$488,000.00
|
$567,000.00
|
$68,173.00
|
-$1.10 M
|
Income Before Tax |
$293,000.00
|
-$53.80 M
|
-$73.30 M
|
-$62.66 M
|
-$38.22 M
|
-$33.53 M
|
-$21.90 M
|
-$15.02 M
|
-$8.88 M
|
-$8.18 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
-18.63
|
-9.24
|
-9.97
|
-1.11
|
-1.39
|
-1.34
|
-4.54
|
Income Tax Expense |
$521,000.00
|
$2,000.00
|
$3,000.00
|
-$1,000.00
|
$2,000.00
|
-$3,000.00
|
$10,000.00
|
-$3,000.00
|
-$20,158.00
|
-$40,018.00
|
Net Income |
-$228,000.00
|
-$53.80 M
|
-$73.30 M
|
-$62.66 M
|
-$38.22 M
|
-$33.53 M
|
-$21.91 M
|
-$15.01 M
|
-$8.86 M
|
-$8.14 M
|
Net Income Ratio |
0
|
0
|
0
|
-18.63
|
-9.24
|
-9.97
|
-1.11
|
-1.39
|
-1.34
|
-4.52
|
EPS |
-0.0074 |
-2.27 |
-3.99 |
-3.49 |
-2.13 |
-1.87 |
-2.74 |
-2.16 |
-1.51 |
-1.74 |
EPS Diluted |
-0.0074 |
-2.27 |
-3.99 |
-3.49 |
-2.13 |
-1.87 |
-2.74 |
-2.16 |
-1.51 |
-1.74 |
Weighted Average Shares Out |
$31.02 M
|
$23.69 M
|
$18.39 M
|
$17.94 M
|
$17.94 M
|
$17.94 M
|
$7.98 M
|
$6.96 M
|
$5.87 M
|
$4.69 M
|
Weighted Average Shares Out Diluted |
$31.02 M
|
$23.69 M
|
$18.39 M
|
$17.94 M
|
$17.94 M
|
$17.94 M
|
$7.98 M
|
$6.96 M
|
$5.87 M
|
$4.69 M
|
Link |
|
|
|
|
|
|
|
|
|
|